Suppr超能文献

调节嵌合抗原受体(CAR)对表皮生长因子受体(EGFR)密度的敏感性可在维持强大抗肿瘤活性的同时限制对正常组织的识别。

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

作者信息

Caruso Hillary G, Hurton Lenka V, Najjar Amer, Rushworth David, Ang Sonny, Olivares Simon, Mi Tiejuan, Switzer Kirsten, Singh Harjeet, Huls Helen, Lee Dean A, Heimberger Amy B, Champlin Richard E, Cooper Laurence J N

机构信息

Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas. The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas.

Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Cancer Res. 2015 Sep 1;75(17):3505-18. doi: 10.1158/0008-5472.CAN-15-0139.

Abstract

Many tumors overexpress tumor-associated antigens relative to normal tissue, such as EGFR. This limits targeting by human T cells modified to express chimeric antigen receptors (CAR) due to potential for deleterious recognition of normal cells. We sought to generate CAR(+) T cells capable of distinguishing malignant from normal cells based on the disparate density of EGFR expression by generating two CARs from monoclonal antibodies that differ in affinity. T cells with low-affinity nimotuzumab-CAR selectively targeted cells overexpressing EGFR, but exhibited diminished effector function as the density of EGFR decreased. In contrast, the activation of T cells bearing high-affinity cetuximab-CAR was not affected by the density of EGFR. In summary, we describe the generation of CARs able to tune T-cell activity to the level of EGFR expression in which a CAR with reduced affinity enabled T cells to distinguish malignant from nonmalignant cells.

摘要

相对于正常组织,许多肿瘤会过度表达肿瘤相关抗原,如表皮生长因子受体(EGFR)。这限制了经改造表达嵌合抗原受体(CAR)的人类T细胞的靶向作用,因为存在对正常细胞进行有害识别的可能性。我们试图通过从亲和力不同的单克隆抗体生成两种CAR,来产生能够基于EGFR表达密度差异区分恶性细胞与正常细胞的CAR(+) T细胞。具有低亲和力尼妥珠单抗-CAR的T细胞选择性地靶向过度表达EGFR的细胞,但随着EGFR密度降低,其效应器功能减弱。相比之下,携带高亲和力西妥昔单抗-CAR的T细胞的激活不受EGFR密度的影响。总之,我们描述了能够将T细胞活性调节至EGFR表达水平的CAR的产生,其中亲和力降低的CAR使T细胞能够区分恶性细胞与非恶性细胞。

相似文献

4
Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Mol Ther. 2017 Nov 1;25(11):2466-2476. doi: 10.1016/j.ymthe.2017.07.009. Epub 2017 Jul 20.
5
Redirecting gene-modified T cells toward various cancer types using tagged antibodies.
Clin Cancer Res. 2012 Dec 1;18(23):6436-45. doi: 10.1158/1078-0432.CCR-12-1449. Epub 2012 Oct 2.
6
Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
J Immunother. 2016 Jun;39(5):205-17. doi: 10.1097/CJI.0000000000000126.
9
Masked Chimeric Antigen Receptor for Tumor-Specific Activation.
Mol Ther. 2017 Jan 4;25(1):274-284. doi: 10.1016/j.ymthe.2016.10.011.

引用本文的文献

2
Adoptive cell therapy for cancer: combination strategies and biomarkers.
Front Immunol. 2025 Aug 1;16:1603792. doi: 10.3389/fimmu.2025.1603792. eCollection 2025.
3
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.
Immunotargets Ther. 2025 Jun 27;14:655-680. doi: 10.2147/ITT.S519616. eCollection 2025.
4
B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer.
J Immunother Cancer. 2025 May 26;13(5):e011533. doi: 10.1136/jitc-2025-011533.
6
SynNotch CAR-T cell, when synthetic biology and immunology meet again.
Front Immunol. 2025 Apr 16;16:1545270. doi: 10.3389/fimmu.2025.1545270. eCollection 2025.
7
Tailoring CAR surface density and dynamics to improve CAR-T cell therapy.
J Immunother Cancer. 2025 Apr 29;13(4):e010702. doi: 10.1136/jitc-2024-010702.
8
CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target.
Cancer Immunol Res. 2025 Jun 4;13(6):867-880. doi: 10.1158/2326-6066.CIR-24-1347.
9
Engineering sonogenetic EchoBack-CAR T cells.
Cell. 2025 May 15;188(10):2621-2636.e20. doi: 10.1016/j.cell.2025.02.035. Epub 2025 Apr 2.

本文引用的文献

2
T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.
Clin Exp Immunol. 2015 May;180(2):255-70. doi: 10.1111/cei.12570.
3
Chimeric antigen receptor T cells for sustained remissions in leukemia.
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
5
Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
Cancer Immunol Res. 2014 Nov;2(11):1059-70. doi: 10.1158/2326-6066.CIR-14-0051. Epub 2014 Aug 7.
9
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.
Sci Transl Med. 2013 Dec 11;5(215):215ra172. doi: 10.1126/scitranslmed.3006597.
10
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects.
Cancers (Basel). 2011 Apr 18;3(2):2014-31. doi: 10.3390/cancers3022014.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验